Screener
Immix Biopharma, Inc. IMMX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Financing Activities: | ||
| Proceeds from exercise of stock options | 33,532 | - |
| Payments of deferred offering costs | (71,093) | - |
| Net cash provided by financing activities | (37,561) | - |
| Effect of foreign currency on cash | (12,813) | (8,000) |
| Net change in cash and cash equivalents | (14,678,403) | (1,760,853) |
| Cash and cash equivalents – beginning of period | 93,928,566 | 17,681,954 |
| Cash and cash equivalents – end of period | $79,250,163 | $15,921,101 |
Document
FAQ
- What is Immix Biopharma, Inc.'s financing cash flow?
- Immix Biopharma, Inc. (IMMX) reported financing cash flow of -$37.56K in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Immix Biopharma, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude